US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty
Guharoy, Roy ; Krenzelok, Edward P.
Citations
Authors
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Recently, the Food and Drug Administration (FDA) issued emergency use authorization (EUA) of convalescent plasma (CP) for the treatment of COVID-19 hospitalized patients based on a non-peer reviewed open label observational study. Issuance of an EUA without a proven randomized control trial (RCT) sets a dangerous precedent since the premature action drives health care providers and patients away from RCTs that are essential for determining the efficacy and safety of CP. More caution should have been taken based on what was learned from the recently rescinded EUA of hydroxychloroquine and chloroquine debacle which was approved initially based on an anecdotal report. The FDA approval process for determining efficacy and safety must be based solely on data from RCTs to sustain public and professional trust for future treatment or vaccine efforts to be successful.
Source
Guharoy R, Krenzelok EP. FDA Emergency Use Authorization: Glass Half Empty? Clin Infect Dis. 2020 Oct 26:ciaa1653. doi: 10.1093/cid/ciaa1653. Epub ahead of print. PMID: 33104216; PMCID: PMC7665427. Link to article on publisher's site